Loading...
XNASANIP
Market cap1.16bUSD
Jan 10, Last price  
55.04USD
1D
1.62%
1Q
-3.68%
Jan 2017
-9.20%
Name

ANI Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ANIP chart
P/E
61.60
P/S
2.38
EPS
0.89
Div Yield, %
0.14%
Shrs. gr., 5y
9.10%
Rev. gr., 5y
19.28%
Revenues
487m
+53.87%
77,886258,35114,438,621493,0543,780,8291,258,0542,474,237435,1602,300,73630,082,00055,970,00076,322,000128,622,000176,842,000201,576,000206,547,000208,475,000216,136,000316,385,000486,816,000
Net income
19m
P
-12,016,207-9,651,0362,791,273-7,584,435-17,425,178-47,527,768-46,196,216-51,608,504-27,717,739301,00028,747,00015,375,0003,934,000-1,076,00015,494,0006,094,000-22,548,000-42,603,000-47,896,00018,779,000
CFO
119m
P
-10,442,443-8,297,509-4,996,735739,992-15,535,932-18,430,910-40,097,506-47,870,103-25,283,020-5,484,00022,033,00017,264,00027,472,00039,419,00067,074,00045,631,00015,267,0003,322,000-31,203,000118,959,000
Earnings
Feb 26, 2025

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
URL
https://www.anipharmaceuticals.com/
IPO date
May 04, 2000
Employees
600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
486,816
53.87%
316,385
46.38%
Cost of revenue
215,799
161,103
Unusual Expense (Income)
NOPBT
271,017
155,282
NOPBT Margin
55.67%
49.08%
Operating Taxes
1,093
(14,769)
Tax Rate
0.40%
NOPAT
269,924
170,051
Net income
18,779
-139.21%
(47,896)
12.42%
Dividends
(1,625)
(1,625)
Dividend yield
0.16%
0.25%
Proceeds from repurchase of equity
75,568
(501)
BB yield
-7.53%
0.08%
Debt
Debt current
2,411
850
Long-term debt
289,628
287,050
Deferred revenue
Other long-term liabilities
16,527
(44,924)
Net debt
70,918
230,913
Cash flow
Cash from operating activities
118,959
(31,203)
CAPEX
(8,868)
(16,455)
Cash from investing activities
(18,511)
(15,738)
Cash from financing activities
67,439
(5,126)
FCF
285,375
133,673
Balance
Cash
221,121
48,228
Long term investments
8,759
Excess cash
196,780
41,168
Stockholders' equity
(46,423)
(60,267)
Invested Capital
807,779
636,575
ROIC
37.38%
25.49%
ROCE
35.60%
23.61%
EV
Common stock shares outstanding
18,194
16,260
Price
55.14
37.06%
40.23
-12.70%
Market cap
1,003,217
53.36%
654,140
12.70%
EV
1,098,985
909,903
EBITDA
330,808
214,935
EV/EBITDA
3.32
4.23
Interest
26,940
28,052
Interest/NOPBT
9.94%
18.07%